RSV immunization in adults and children: A practical guide for clinicians.

IF 3.4 4区医学 Q1 MEDICINE, GENERAL & INTERNAL

Cleveland Clinic Journal of Medicine Pub Date : 2024-09-04 DOI:10.3949/ccjm.91.s1.03

Trate DeVolld, Kaitlyn R Rivard

引用次数: 0

Abstract

In 2023 and 2024, 3 vaccines were approved by the US Food and Drug Administration (FDA) against respiratory syncytial virus (RSV) in adults. In addition, the first long-acting RSV monoclonal antibody for infants and young children was approved. This review provides clinicians with practical guidance to navigate this new era of RSV prevention.

查看原文本刊更多论文

成人和儿童 RSV 免疫接种：临床医生实用指南。

2023 年和 2024 年，美国食品和药物管理局（FDA）批准了 3 种预防成人呼吸道合胞病毒（RSV）的疫苗。此外，首个用于婴幼儿的长效 RSV 单克隆抗体也获得批准。本综述为临床医生提供了实用的指导，帮助他们在这个预防 RSV 的新时代中游刃有余。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cleveland Clinic Journal of Medicine 医学-医学：内科

CiteScore

3.80

自引率

0.00%

发文量

109

审稿时长

6-12 weeks

期刊介绍： The mission of Cleveland Clinic Journal of Medicine (CCJM) is to provide its readers with up-to-date, practical, clinical information relevant to internal medicine, cardiology, and related fields. Consistent with this mission, CCJM focuses on timely review articles and other content that has a continuing-education orientation rather than on original research or case reports. CCJM authors, drawn from Cleveland Clinic and other top medical institutions throughout the world, are asked to identify new findings that are changing the practice of medicine and to advise readers how to apply them in daily patient care. Authors are chosen for their experience, acquired through caring for patients, teaching other physicians, and researching clinical questions.